Loading...

The current price of TELO is 1.445 USD — it has decreased -0.34 % in the last trading day.
Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
Wall Street analysts forecast TELO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TELO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Telomir Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.
Telomir Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -85.00 % YoY.
Telomir Pharmaceuticals Inc (TELO) has 0 emplpoyees as of December 15 2025.
Today TELO has the market capitalization of 49.85M USD.